Donald S. Burke (IOM), is the Dean of the Graduate School of Public Health, Director of the Center for Vaccine Research and Associate Vice Chancellor for Global Health at the University of Pittsburgh. He is also the first occupant of the UPMC-Jonas Salk Chair in Global Health and a Distinguished University Professor of Health Science and Policy. He was an intern and resident in medicine at Boston City and Massachusetts General Hospitals and trained as a research fellow in infectious diseases at the Walter Reed Army Medical Center. Dr. Burke has expertise in the prevention and control of infectious diseases of global concern, including HIV/AIDS, influenza, dengue, and emerging infectious diseases. He is an Institute of Medicine member and has served on previous NRC and IOM committees, including the Committee on the Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents and the Committee on Assessment of Future Scientific Needs for Live Variola Virus. Dr. Burke received his BA from Western Reserve University and his MD from Harvard Medical School.
L. Garry Adams is Professor of Veterinary Pathology and former Associate Dean for Research & Graduate Studies for the College of Veterinary Medicine at Texas A&M University. He began his career with the International Programs division of Texas A&M University where he worked for seven years with the Rockefeller Foundation, USAID and other organizations living on four continents and in over 15 countries where he developed and led programs in research on infectious and zoonotic diseases of domestic animals and established international program linkage projects. For almost two decades, he was involved in improving the scientific basis of the two largest animal health regulatory programs in the USA, brucellosis and tuberculosis. He has been very active in developing and implementing biodefense and emerging diseases research initiatives, and he has provided expert testimony to the US House Committee for Homeland Defense as well as serving on the National Institutes of Health, Biodefense & Emerging Diseases, Blue Ribbon Committee for Category B and C Pathogens. He served on the National Academy of Science, Standing Committee for the Department of Defense Transformational Medical Technologies. He was the Scientific Leader for the Biological Systems division of the Department of Homeland Security, National Center for Foreign Animal Disease & Zoonotic Disease Defense, served on the American Veterinary Medical Association (AVMA) Council on Research [2004-2010], is a Commissioner on the Texas Forensic Science Commission [2006-2012], and a member of the AVMA Council on Education. Dr. Adams’ research is focused on the host-pathogen interface, genetic basis of natural disease resistance, molecular pathogenesis of intracellular bacterial pathogens, and the development of vaccines and diagnostic tests against zoonotic diseases. He has authored or co-authored more than 235 original scientific publications in refereed journals, chaired or co-chaired 54 Doctor of Philosophy graduate students’ advisory committees and served as member on 78 graduate student advisory committees. His laboratory has ongoing research on salmonellosis, brucellosis, Johne’s Disease, Rift Valley Fever and African Swine Fever. He has been awarded the Texas Veterinary Medical Association Faculty Achievement Award for Research; USDA National Superior Service Award for Outstanding Research; American Veterinary Medical Association Research Award; Elected Full Member of Academia Veterinaria Mexicana; Faculty Fellow, Texas Agricultural Experiment Station, and the AVMA Lifetime Award for Research Excellence. He has served and is serving on the editorial boards of numerous international research journals. Adams earned his Associate of Science degree from Tarleton State University, and Bachelor of Science in Animal Science, Doctor of Veterinary Medicine and Doctor of Philosophy in Veterinary Pathology degrees from Texas A&M University.
John F. Alderete is Professor of Microbiology at the University of Texas Health Science Center at San Antonio. He received two B.S. degrees (mathematics and biology) as an undergraduate student at New Mexico Institute of Mining and Technology at Socorro. His first and second publications were from work as an undergraduate with Dr. Gilbert Sanchez at Tech and as a student intern with Dr. Tom H. Wilson at the Department of Physiology at Harvard Medical School, respectively. He received his PhD in microbiology in 1978 from the University of Kansas-Lawrence. He did postdoctoral work at UNC-Chapel Hill prior to taking a faculty position at the University of Texas Health Science Center at San Antonio in 1981. He has been director of two training grants from NIAID/NIH. He has over 117 publications in peer-reviewed journals and is the author of 54 book chapters and invited OP-ED editorials. His research on the number one, non-viral sexually transmitted agent, Trichomonas vaginalis, has been presented as abstracts published in 145 proceedings of national and international scientific meetings, where he has also participated in, chaired, and organized scientific symposia. His research has resulted in 6 patents and patents pending. He has an exclusive license agreement between the Board of Regents of UT and Xenotope Diagnostics, Inc. He has been a member of study sections and panels for NIH institutes, the NSF, USDA and other government agencies. He was a member of the National Advisory Research Council for the National Institute of Dental and Craniofacial Research/NIH. He is asked to speak on issues involving minorities, higher education, and the scientific workforce by government agencies. These include the President’s National Science Board, the NIH, the FDA, the White House Office of Science and Technology Policy, and White House “One Nation” on race and health disparities. He was elected into the honorific societies Sigma Xi and as a Fellow of the American Academy of Microbiology by the American Society of Microbiology (ASM), and in the fall of 2001 was honored at the National Atomic Museum in New Mexico. Alderete is the inventor for the first-ever diagnostic for trichomonosis disease and was co-founder of a biotechnology company, Xenotope Diagnostics, Inc. The company is FDA-approved for two products for the diagnosis of Trichomonas STD vaginitis. Finally, Dr. Alderete was recently accepted into the National Academy of Sciences of Mexico.
Stanley N. Cohen (NAS,IOM), is currently Kwoh-Ting Li Professor of Genetics and Professor of Medicine at the Stanford University School of Medicine. The invention of recombinant DNA methodology or “genetic engineering” by Cohen and Herbert W. Boyer constitutes the foundation for what has been called “the new genetics”. In subsequent experiments, Cohen showed that animal cell genes introduced into bacteria could function biologically in their new environment. Dr. Cohen is a magna cum laude graduate of Rutgers University and received his MD from the University of Pennsylvania School of Medicine in 1960. Following training at the National Institutes of Health and elsewhere, Dr. Cohen joined the faculty of Stanford University in 1968. Cohen is the former Chairman of the Department of Genetics at Stanford. He is the recipient of numerous awards, including the National Medal of Science, the National Medal of Technology, the Lasker Award for Basic Medical Research, the Wolf Prize in Medicine, the Research Award of the Helmut Horten Foundation, the Prix de l’Institut de la Vie, and the Lemelson-MIT Prize. He is a member of the NAS and IOM and a Fellow of the American Academy of Arts and Sciences. He has received Sc.D. honoris causa degrees from Rutgers University and the University of Pennsylvania.
Denise L. Faustman is currently Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Dr. Faustman has worked in the field of autoimmunity for over 15 years and has made some of the key discoveries regarding the role of MHC Class I antigen presentation in immunity. Her earlier research achievements include introducing the concept of modifying antigens on donor tissues to prevent their rejection, a scientific accomplishment that is now in human clinical trials for diverse human diseases treatable with cellular transplants. In 2001, her lab reversed type 1 diabetes in mice with end stage disease, a project that is now being translated into human clinical trials. Her current research continues to focus on uncovering new treatments for type 1 diabetes, as well as searching for therapies for other autoimmune diseases, including Crohn’s disease, lupus, scleroderma, rheumatoid arthritis, Sjogren’s syndrome, and multiple sclerosis After completing her internship, residency, and fellowships in Internal Medicine and Endocrinology at the MGH, Dr. Faustman became an independent investigator at the MGH and Harvard Medical School in 1987. She is a member of the American Association for the Advancement of Science (AAAS) and has served on several NRC and IOM committees including the NRC Standing Committee on Biodefense for the U.S. Department of Defense. In 2003, Dr. Faustman was honored by National Institutes of Health and the National Library of Medicine, with the “Changing the Face of Medicine” award. She was one of 300 American physicians honored for achievement in medicine, past and present. In 2005, she received the Oprah Achievement Award, Top Health Breakthrough by a Female Scientist. In 2006, she was awarded the Women in Science Award, American Medical Women’s Association and Wyeth Pharmaceutical Company given to a female physician who has made exceptional contributions to medical science through basic science publications and through leadership in the field.
John Grabenstein is Executive Director for Medical Affairs and Policy for Merck Vaccines. He provides scientific advice for Merck’s global vaccine enterprise, to reduce the burden of vaccine-preventable diseases worldwide. His duties focus on vaccination initiatives for pneumococcal disease and herpes zoster (“shingles”), vaccines with more than 15 million doses distributed globally each year. A pharmacist with over 30 years experience, he has published over 300 articles and eight books, primarily on immunization, public health, and leadership. Previously, as a Colonel in the United States Army, Dr. Grabenstein directed the Military Vaccine Agency, where he oversaw Defense Department immunization programs for 9 million troops, retirees, and family members spread across 4 continents and dozens of ships at sea. In 1996, he wrote the curriculum for “Pharmacy-Based Immunization Delivery,” a CDC-recognized 20-hour course coordinated by the American Pharmacists Association (APhA). Dr. Grabenstein received his pharmacy degree from Duquesne University in 1980, a master’s degree in education from Boston University in 1988, then his doctorate in epidemiology at the University of North Carolina in 1999.
Diane E. Griffin (NAS,IOM), is Professor and Department Chair of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. Dr. Griffin is a world leader in the study of the pathogenesis of viral infections and the viral determinants of virulence and the host responses to infection viral pathogenesis. She has elucidated mechanisms that control Sindbis virus neurovirulence, and her pioneering work on measles virus has revealed the basis for the profound immunosuppression caused by measles infection and for the development of severe atypical measles. She was elected to both the IOM and the NAS in 2004. She currently serves as a member of the Editorial Board for PNAS and on the Committee on Defense Intelligence Agency Technology Forecasts and Reviews. Dr. Griffin holds a PhD and MD from Stanford University.
John M. Hardham is Associate Research Fellow, Global Biologicals Research and Technical Lead, Emerging Infectious Disease Program at Zoetis, Inc. (formerly Pfizer Animal Health). Dr. Hardham also serves in the United States Navy Reserve as Medical Director and Commander of Naval Forces Korea. After completion of his postdoctoral fellowship at the University of Texas Medical School in Houston, TX he became a research scientist for Pfizer, Inc. Dr. Hardham accepted a direct commission into the U.S. Navy Reserves as a Lieutenant Junior Grade in 1994. Over the next decade, he served at several hospitals around the country, as Environmental Health Officer and Administrative Officer, before being mobilized into active duty for the Iraq War in 2004. Dr. Hardham served as the Microbiology Lab Director and Preventive Medicine Mobile Medical Augmentation Response Team (PM-MMART) Microbiologist for Navy Environmental Preventative Medicine Unit 6, Pearl Harbor, HI. He has since served on numerous committees and in advisory roles to DoD, HHS, and has made briefings to various House and Senate Committees, Intelligence Community Programs, Executive Office Committees, and the National Security Council. From 2001 – 2009, Dr. Hardham was assigned to the Office of the Assistant Secretary of Defense for Nuclear and Chemical and Biological Defense Programs, where he served as the Medical Director, and directed the Department of Defense Medical Countermeasure Development Program. Dr. Hardham’s personal decorations include The Joint Service Commendation Medal (awarded by the Secretary of Defense, Robert Gates), Navy Achievement Medal (six awards), National Defense Service Medal, Armed Forces Reserve Medal (Bronze M), and Outstanding Volunteer Service Medal. He received a BS in Microbiology from The Pennsylvania State University, and MS and PhD degrees in Microbiology from the University of North Carolina, Chapel Hill.
Kendall Hoyt is an Assistant Professor at Dartmouth Medical School and a Lecturer at the Thayer School of Engineering at Dartmouth College. Dr. Hoyt studies biosecurity strategy and biomedical research policy. She is the author of Long Shot: Vaccines for National Defense, Harvard University Press (2012). Prior to coming to Dartmouth, she was an International Security Fellow at the Belfer Center for Science and International Affairs at Harvard University. She has worked for the Executive Session for Domestic Preparedness at Harvard University, the National Security and International Affairs division of the White House Office of Science and Technology Policy, McKinsey and Company, and the Center for the Management of Innovation and Technology at the National University of Singapore. She received a BA in from Duke University in 1993 and a PhD from MIT in 2002.
Paul Keim holds the E. Raymond and Ruth Cowden Endowed Chair in Microbiology and is a Regents Professor of Biology at Northern Arizona University. In addition, he directs the Pathogen Genomics Division at The Translational Genomics Research Institute (Tgen) in Flagstaff, Arizona. His biological interests span many types of organisms and microbes, but revolve around genetic diversity and its organization in populations and species. This necessarily has involved systematic and phylogenetic analyses to understand how observable genetic diversity is based upon past evolutionary processes. Biodefense programs have capitalized upon his approach of using genomic analysis to understand bacterial pathogen populations for microbial forensics and molecular epidemiological analyses. His laboratory was heavily involved in analysis of evidentiary material from the 2001 anthrax-letter attacks. He has published extensively on the evolution and population genetics of Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia pseudomallei, Burkholderia mallei, Brucella spp., and Coxiella burnetii. Recently, these same principles have been applied to other public health-related and clinically important pathogens such as S. aureus and E. coli. Dr. Keim has previously served on the editorial boards of Crop Science and Molecular Breeding; he currently serves on the editorial boards of Infection Genetics and Evolution, Investigative Genetics, and Biotechniques. His graduate work was focused on the biochemistry of plant hormones and growth regulators, in particular cytokinins. Making a dramatic career switch to bacterial genetics and genomics, he did postdoctoral work with Gordon Lark at the University of Utah from 1981 to 1987. It was here that he became immersed in bacterial genetics and eventually genomics, through the characterization of the low homology E. coli recE and the lambda phage Red recombination systems. A second postdoctoral stint at Iowa State University was devoted to soybean genetics and genome mapping using novel molecular tools to identify quantitative trait loci (QTL). Dr. Keim received his BS in Biology and Chemistry from Northern Arizona University in 1977 and his PhD in Botany in 1981 from the University of Kansas.
Thomas Ksiazek is Professor, Departments of Pathology and Microbiology and Immunology, University of Texas Medical Branch; Senior Staff Scientist and Director, High Containment Operations Core, Galveston National Laboratory; and Director, University of Texas Medical Branch National Biocontainment Training Center. Previously, he was the Chief, Special Pathogens Branch at the CDC after retiring from the U.S. Army as Lieutenant Colonel. Dr. Ksiazek has worked as a Veterinary Microbiologist in virology at research at stations around the world for the U.S. Navy, U.S. Air Force and then for the U.S. Army at the Disease Assessment Division, at Ft. Detrick in Frederick, Maryland. He then served as Chief, Rapid Diagnosis Section, Department of Epidemiology, Disease Assessment Division, at Ft. Detrick. Dr. Ksiazek has authored and co-authored over 330 publications in his career and is a member of the American Society of Tropical Medicine and Hygiene, American Society for Microbiology, American Association for the Advancement of Science, American Veterinary Medical Association, the Society of Tropical Veterinary Medicine and is a member of the Phi Zeta Honor Society. Dr. Ksiazek received a master’s degree in Virology from the University of Wisconsin, Madison, a PhD in Epidemiology and Virology from the University of California, Berkeley, and a DVM from Kansas State University.
Anthony S. Lubiniecki is Senior Scientific Director & Fellow within Pharmaceutical Development & Manufacturing Sciences at Janssen R & D, LLC. He is responsible for review of technical content of internal development projects for biotechnology- derived products, review and approval of regulatory filiings, and improving the efficiency of development projects. Previously, he spent 16 years at GlaxoSmithKline Pharmaceuticals (and its predecessor firms) where he held executive positions in both development and clinical manufacturing. Prior to joining GSK, Dr. Lubiniecki was at Genentech where he was responsible for integrating quality concepts into manufacturing and development as well as directing the Cell Culture R&D group. Lubiniecki has been active in shaping regulatory policy by serving as a PhRMA representative to the International Conferences (ICH) on Harmonization Expert Working Groups on Specifications (Q6B), Active Pharmaceutical Ingredients (Q7A), Genetic Stability (Q5C), and Viral Safety (Q5A) as well as the rapporteur for Cell Substrates (Q5D) and Comparability (Q5E). He served on the HHS Secretary Advisory Committee on Xenotransplantation, and as a member of the Material Technical Advisory Committee to the Department of Commerce, and has served on the Review Committee for Research at the Center for Biologics Evaluation and Research, FDA. He was elected to chair the Biotechnology Products Committee of the US Pharmacopeia in 2000. He received the Hyclone Award from the European Society for Animal Cell Technology in 1991 for distinguished contributions to biotechnology. He is also Adjunct Professor of Chemical and Biochemical Engineering at University of Maryland, Baltimore County since 1990. Dr. Lubiniecki is a member of the Board of Directors of the International Association for Biologicals.
C. Rick Lyons is Director of the Infectious Disease Research Center at Colorado State University. Dr. Lyons is a physician scientist trained as a Hematologist/Oncologist. Previously, he was at the University of New Mexico Health Science Center in Albuquerque where he was professor of Medicine and Director of the Center for Infectious Diseases and Immunology. His scientific expertise is in developing animal models of human diseases that can be used to translate products into humans. There are three main emphases in his research: 1) Develop the most accurate animal models of infection that mimic human disease; 2) Apply cutting edge technology to analyze the endpoints during in vivo infection; and 3) Develop strong collaborations with internal and external investigators to bring the most expertise to bear on these issues. In the last ten years he has focused his research on a variety of emerging infections particularly in the field of bioweapons including Bacillus anthracis and Francisella tularensis using a variety of species to examine their pathogenesis including mice, rats, rabbits and primates. He received his MD and doctorate from University of Texas Southwestern Medical School in Dallas, Texas. and his PhD in Immunology and Hematology/Oncology training at the Brigham and Women’s Hospital in Boston, Massachusetts. He has previously served on the NRC Committee on Determining Core Capabilities in Chemical and Biological Defense Research and Development and the NRC Committee on Animal Models for Assessing Countermeasures to Bioterrrorism Agents.
Melinda Moore is a public health physician and senior natural scientist at the RAND Corporation. Before joining RAND, Moore served with the Centers for Disease Control and Prevention for 20 years and the Department of Health and Human Services’ Office of Global Health Affairs for 5 years. Her principal career focus has been global health; her expertise includes child health, infectious disease surveillance and control, environmental health, health security, and health diplomacy. At RAND, she has focused on infectious disease surveillance, public health preparedness, military health, and environmental health. Public health preparedness projects she has led or participated in have assessed response to potential anthrax incidents; identified strategies for improving global influenza surveillance; implemented tabletop pandemic influenza preparedness exercises in the United States, Southeast Asia, and Middle East; assessed the U.S. health response to the H1N1 influenza pandemic; and supported development of the National Health Security Strategy. She has led or co-led military health projects related to medical intelligence, community disaster preparedness, the DoD Serum Repository, Army veterinarians in stability operations, and evaluation of humanitarian assistance efforts. She led RAND’s contributions to a national environmental health strategy for the United Arab Emirates and is co-leading a project to improve primary care in the Kurdistan region of Iraq. Moore is board certified in pediatrics and preventive medicine, has worked in more than 45 countries, and speaks five languages. She is a retired Medical Officer (Captain, O6) of the U.S. Public Health Service. Moore’s previous positions include Deputy Director, Office of Global Health Affairs, U.S. Department of Health and Human Services; Associate Director for Global Health, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC); Acting Associate Director for Global Health, CDC; first chair of the Asia Pacific Economic Cooperation’s Health Task Force.
Stephen S. Morse is a Professor of Clinical Epidemiology at the Columbia University Mailman School of Public Health. His interests focus on epidemiology of infectious diseases and improving disease early warning systems. In 2000, he returned to Columbia after 4 years in government as program manager for Biodefense at the Defense Advanced Research Projects Agency (DARPA), Department of Defense, where he co-directed the Pathogen Countermeasures program and subsequently directed the Advanced Diagnostics program. Before coming to Columbia, he was an assistant professor of Virology at The Rockefeller University in New York, and remains an adjunct faculty member there. His book, Emerging Viruses (Oxford University Press) was selected by “American Scientist” for its list of “100 Top Science Books of the 20th Century”. Dr. Morse was chair and principal organizer of the 1989 NIAID/NIH (National Institutes of Health) Conference on Emerging Viruses, for which he originated the term and concept of emerging viruses/infections; served as a member of the Institute of Medicine/National Academy of Sciences’ Committee on Emerging Microbial Threats to Health (and chaired its Task Force on Viruses), and was a contributor to its report, Emerging Infections (1992). He currently serves on the Steering Committee of the IOM’s Forum on Microbial Threats, and the NAS’s Committee on Future Biowarfare Threats; and has served as an adviser to numerous government and international organizations. He was the founding chair of ProMED (the nonprofit international Program to Monitor Emerging Diseases) and was one of the originators of ProMED-mail, an international network inaugurated by ProMED in 1994 for outbreak reporting and disease monitoring using the Internet. He received his PhD from the University of Wisconsin.
Karen E. Nelson is the Director of the Rockville Campus of the J. Craig Venter Institute (JCVI) where she has worked for the past 15 years. She was formerly the Director of Human Microbiology and Metagenomics in the Department of Human Genomic Medicine at the JCVI. Dr. Nelson has extensive experience in microbial ecology, microbial genomics, microbial physiology, and metagenomics. Since joining the JCVI legacy institutes, Dr. Nelson has led several genomic and metagenomic efforts, was involved in the analysis of the microbiota of the human stomach and gastrointestinal tract, and led the first human metagenomics study on fecal material derived from three individuals which was published in 2006. Additional ongoing studies in her group include metagenomic approaches to study the ecology of the gastrointestinal tract of humans and animals, reference genome sequencing and analysis, studies with non-human primates, and studies on the relationship between the microbiome and various human and animal disease conditions. She has authored or co-authored over 100 peer reviewed publications and edited three books, and is currently Editor-in-Chief of the journals Microbial Ecology and Advances in Microbial Ecology. She also serves on the editorial boards of BMC Genomics, GigaScience, and the Central European Journal of Biology. She is also a Fellow of the American Society for Microbiology. Dr. Nelson received her undergraduate degree from the University of the West Indies, and her PhD from Cornell University.
Tom Slezak has been involved with bioinformatics at Lawrence Livermore National Laboratory (LLNL) for 30 years after receiving BS and MS degrees in Computer Science from the University of California, Davis. Slezak is currently the Associate Program Leader for Informatics for the Global Security Program efforts at LLNL. He was involved with the Human Genome Program from 1987-2000, leading the informatics efforts at LLNL and then the DOE’s Joint Genome Institute from 1997-2000. In 2000 he began to build a pathogen bioinformatics team at LLNL, pioneering a novel whole-genome analysis approach to DNA signature design. His team developed signature targets for multiple human pathogens that were used at the 2002 Winter Olympic Games under the BASIS program and later adapted for use nationwide in the DHS BioWatch program. Under a close collaboration with the CDC, the LLNL team has been called on for computational help on smallpox, SARS, monkeypox, avian influenza, and numerous other pathogens. In addition to continuing work on human and agricultural pathogens, Slezak’s team is currently focusing on signatures of mechanisms of virulence, antibiotic-resistance, and evidence of genetic engineering. They have been focusing on detecting novel, engineered, and advanced biothreats for several years. Slezak has chaired or served on multiple advisory boards, including the rice genome project, mouse and maize genetics databases, spruce tree genome project (Canada), plant pathogens, and an NIH/NIAID sequencing center contract renewal. He has served on NRC committees, including Scientific Milestones for Select Agents and Determining Core Capabilities in Chemical and Biological Defense Research and Development.
Douglas B. Weibel is an Assistant Professor of Biochemistry, Chemistry and Biomedical Engineering at the University of Wisconsin-Madison. Dr. Weibel studies the biochemistry, physiology, and behavior of microorganisms and has a long-term interest in developing strategies and technologies for diagnosing and treating infectious agents. Prior to beginning a faculty position at UW-Madison in 2006, he was a postdoctoral fellow in chemistry and engineering with G. M. Whitesides at Harvard University. Dr. Weibel has consulted for several governmental organizations (including the FDA) and has been a visiting scientist at Google[x], Orchid Cellmark (acquired by LabCorp), and the Max Planck Institute for Chemical Ecology. Following his BS in chemistry from the University of Utah, Dr. Weibel spent 1996 – 1997 as a Fulbright Fellow in Japan (Tohoku University). He received a PhD in chemistry from Cornell in 2002.